Alyeska Investment Group L.P. Acquires New Stake in Spark Therapeutics Inc (ONCE)
Alyeska Investment Group L.P. acquired a new stake in Spark Therapeutics Inc (NASDAQ:ONCE) during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 151,621 shares of the biotechnology company’s stock, valued at approximately $13,519,000. Alyeska Investment Group L.P. owned about 0.41% of Spark Therapeutics at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Ameritas Investment Partners Inc. increased its position in shares of Spark Therapeutics by 23.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 389 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Spark Therapeutics in the 2nd quarter valued at approximately $143,000. Teacher Retirement System of Texas purchased a new stake in shares of Spark Therapeutics in the 3rd quarter valued at approximately $225,000. Prudential Financial Inc. purchased a new stake in shares of Spark Therapeutics in the 3rd quarter valued at approximately $239,000. Finally, Commonwealth Equity Services Inc purchased a new stake in shares of Spark Therapeutics in the 3rd quarter valued at approximately $257,000. 94.94% of the stock is currently owned by institutional investors.
A number of brokerages have commented on ONCE. Raymond James Financial reissued a “buy” rating on shares of Spark Therapeutics in a research report on Thursday. BMO Capital Markets reissued a “buy” rating and issued a $101.00 price objective on shares of Spark Therapeutics in a research report on Wednesday, November 15th. ValuEngine downgraded shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Royal Bank Of Canada lowered their target price on shares of Spark Therapeutics from $100.00 to $98.00 and set an “outperform” rating for the company in a report on Wednesday, November 8th. Finally, SunTrust Banks set a $101.00 target price on shares of Spark Therapeutics and gave the company a “buy” rating in a report on Monday, October 16th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and eighteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $90.36.
Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.11). The business had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The firm’s revenue for the quarter was up 45.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.07) EPS. analysts forecast that Spark Therapeutics Inc will post -7.6 earnings per share for the current fiscal year.
In related news, insider Daniel Faga sold 1,500 shares of the stock in a transaction on Tuesday, September 19th. The shares were sold at an average price of $85.00, for a total transaction of $127,500.00. Following the completion of the sale, the insider now owns 1,500 shares in the company, valued at approximately $127,500. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Barge Joseph La sold 5,500 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $71.44, for a total transaction of $392,920.00. Following the sale, the insider now owns 8,146 shares of the company’s stock, valued at approximately $581,950.24. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,074,809 shares of company stock valued at $90,304,385. 7.30% of the stock is owned by company insiders.
TRADEMARK VIOLATION WARNING: “Alyeska Investment Group L.P. Acquires New Stake in Spark Therapeutics Inc (ONCE)” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/alyeska-investment-group-l-p-acquires-new-stake-in-spark-therapeutics-inc-once/1756926.html.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.